Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.66 |
| ▸ | NPY4R | P50391 | 8/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.66 |
| ▸ | NPY1R | P25929 | 8/20 | 0.66 |
| ▸ | RAMP3 | O60896 | 6/20 | 0.63 |
| ▸ | CALCR | P30988 | 6/20 | 0.63 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.62 |
| ▸ | TFPI | P10646 | 1/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30607310 | 0.88 | CALCR (0.66) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30397368 | 0.87 | NPY2R (0.82) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL30574247 | 0.86 | NPY2R (0.74) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL30436941 | 0.86 | CALCR (0.64) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30262071 | 0.86 | KEAP1 (0.62) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL29977603 | 0.86 | NPY2R (0.69) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL9979655 | 0.85 | NPY2R (0.69) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30495784 | 0.85 | NPY2R (0.70) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31050076 | 0.84 | GLP1R (0.66) | NPY2RNPY4RNPY5RNPY1RCXCR4 | |
| SCHEMBL29754385 | 0.84 | MAPK8 (0.64) | NPY2RNPY4RNPY5RNPY1RRAMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12612445-B2 | Therapeutic agents | KING'S COLLEGE LONDON (GB) | 2026-04-28 | — | — | US | disclosed |
| US-12509499-B2 | Therapeutic agents | KING'S COLLEGE LONDON (GB) | 2025-12-30 | — | — | US | disclosed |
| WO-2024263637-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-118510814-A | Chimeric antigen receptor and application thereof | 星尘生物科技(上海)有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240228576-A1 | THERAPEUTIC AGENTS | KING'S COLLEGE LONDON (GB) | 2024-07-11 | — | — | US | disclosed |
| US-20240101601-A1 | BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240076348-A1 | THERAPEUTIC AGENTS | KING'S COLLEGE LONDON (GB) | 2024-03-07 | — | — | US | disclosed |
| WO-2023217062-A1 | CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 星尘生物科技(上海)有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-11802143-B2 | Therapeutic agents | KING'S COLLEGE LONDON (GB) | 2023-10-31 | — | — | US | disclosed |
| US-20230183317-A1 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-15 | — | — | US | disclosed |
| EP-4146268-A2 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | The Regents of the University of California (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11485758-B2 | Bi-terminal pegylated integrin-binding peptides and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-01 | — | — | US | disclosed |
| EP-3131566-B1 | BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-107735407-B | Therapeutic agents | 伦敦国王学院 | 2022-08-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509499-B2 | Therapeutic agents | IL2RA, CD4, TNFRSF9 | NPY2R 421/4885NPY4R 659/4885NPY5R 1156/4885 |
| US-12612445-B2 | Therapeutic agents | CD40, TNFRSF9, HAVCR2 | NPY2R 768/4885NPY4R 722/4885NPY5R 1499/4885 |
| US-20230183317-A1 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | ACE2, ACE, MAVS | NPY2R 4258/4885NPY4R 4508/4885NPY5R 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.